New data from an open-label extension study of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)’s Onpattro shows long-term efficacy and sustained treatment benefit for polyneuropathy of hereditary ATTR …
Tag: LEA
New data from an open-label extension study of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)’s Onpattro shows long-term efficacy and sustained treatment benefit for polyneuropathy of hereditary ATTR …